Test the patient. Test the tumor.
NGS and PGx are often viewed as two separate components. However, the two combined offer groundbreaking benefits for cancer treatment and oncology practices. Introduced in the early stages of cancer, this integrated approach can enhance and extend patients’ lives.
CompanionDx’s abstract “Role of combined germline pharmacogenomic and somatic genomic analysis in personalized cancer therapy” was published online by the American Society of Clinical Oncology (ASCO) as part of their annual meeting, May 29 – June 2 in Chicago. Read full abstract.